Medline Inc. reported strong top-line growth in Q4 and FY2025, driven by increased volumes across its segments. However, profitability metrics like net income and operating margin declined year-over-year due to higher costs, including tariffs, investments, and IPO-related expenses. The company also completed its initial public offering, a significant strategic milestone.
Net sales in the fourth quarter increased by 14.8% to $7.8 billion, with full year net sales growing 11.5% to $28.4 billion.
positiveOrganic sales grew 14.4% in Q4 and 10.5% for the full year, indicating strong underlying business performance.
positiveCompleted a successful initial public offering, strengthening the company's foundation for future investments and growth.
positiveFull year 2025 Adjusted EBITDA increased by 3.2% to $3.5 billion.
positiveFourth quarter net income decreased by 37.7% to $180 million, and full year net income decreased by 3.6% to $1.2 billion, primarily due to higher costs of goods sold and operating expenses.
negativeOperating income for Q4 decreased by 13.6% to $425 million, and operating margin compressed from 7.3% to 5.5%.
negativeFourth quarter Adjusted EBITDA decreased by 0.6% to $805 million, despite revenue growth.
attentionGross margin declined to 24.6% in Q4 2025 from 27.3% in Q4 2024.
negativeFull year 2025 Free Cash Flow decreased by 8.3% to $1.3 billion.
attentionInventories increased by $313 million year-over-year, outpacing net sales growth.
attentionMargin expansion indicates improving profitability and operational efficiency. Measured in basis points (bps): 100 bps = 1.0%.
| Segment | Current | Prior Yr | YoY | % Total |
|---|---|---|---|---|
Medline Brand segment | N/A | — | — | — |
Supply Chain Solutions segment | N/A | — | — | — |
| Total Revenue | $0.00M | — | — | 100.0% |
Segment performance shows business unit health and growth drivers.
Forward-looking guidance is subject to change and does not constitute a guarantee. Actual results may differ materially from these estimates.
Special items are non-recurring events that may distort period-over-period comparisons. Analysts typically adjust for these when calculating normalized earnings.
Delivered strong fourth quarter results, concluding a successful 2025 with $2.4 billion in total new customer signings.
Performance reflects customer confidence in value, service, and reliability, and our unique capability to support health systems across the entire continuum of care.
The quarter also marked a major milestone with the completion of our successful initial public offering.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.